Skip to main content
🥗 Does diet improve PsA?

DIPSA RCT: Mediterranean/DASH/Standard all improved DAPSA in 92pts

Weight loss drove outco

Nelly ZIADE 🍀 Nellziade

1 month 3 weeks ago
🥗 Does diet improve PsA? DIPSA RCT: Mediterranean/DASH/Standard all improved DAPSA in 92pts Weight loss drove outcomes OP070 #EULAR2026 @RheumNow https://t.co/k5y7bvDbDQ
Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA:
Females ⬆️ dse

sheila RHEUMarampa

1 month 3 weeks ago
Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA: Females ⬆️ dse act (asdas,basdai) ⬆️enthesitis scores, S/TJCts Males ⬆️rate of xray prog(msasss) Sex diffs exist in SpA Need for sex-specific mgt AbsOP0101 @Rheumnow #EULAR2026 https://t.co/qiNzDFh08v
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in

Md Yuzaiful Md Yusof Yuz6Yusof

1 month 3 weeks ago
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua
The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't

Dr. John Cush RheumNow

1 month 3 weeks ago
The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't spend hours sorting through hundreds of abstracts; RheumNow will do it for you. Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty as they break down the https://t.co/eAPV6h5FAn
♂♀ Does sex matter in #axSpA long-term?

GESPIC (n=525,10y):
Yes! ♂ less symptoms but 2x more spinal progression

Nelly ZIADE 🍀 Nellziade

1 month 3 weeks ago
♂♀ Does sex matter in #axSpA long-term? GESPIC (n=525,10y): Yes! ♂ less symptoms but 2x more spinal progression #OP0101 #EULAR2026 @RheumNow https://t.co/znFXWyrfZl
🔍 What defines a positive MRI for #axSpA?

SPARTAN-SSR consensus (n=1,050):
BME≥3 slices or 2/3 lesions in ≥3 SI

Nelly ZIADE 🍀 Nellziade

1 month 3 weeks ago
🔍 What defines a positive MRI for #axSpA? SPARTAN-SSR consensus (n=1,050): BME≥3 slices or 2/3 lesions in ≥3 SIJ quadrants #OP0100 #EULAR2026 @RheumNow https://t.co/nfhzGxBZOm
HLA-Cw6: a marker of more severe and difficult to manage psoriatic arthritis?

POS0484
#EULAR2026
@RheumNow https://t.co

Nelly ZIADE 🍀 Nellziade

1 month 3 weeks ago
HLA-Cw6: a marker of more severe and difficult to manage psoriatic arthritis? POS0484 #EULAR2026 @RheumNow https://t.co/MIYZxuYT4v
Interesting pilot study using line-field confocal OCT for CLE

The “virtual biopsy” identified distinct layer-specif

sheila RHEUMarampa

1 month 3 weeks ago
Interesting pilot study using line-field confocal OCT for CLE The “virtual biopsy” identified distinct layer-specific patterns across diff CLE subtypes including distinctions bet ACLE & rosacea (dil. vessels, demodex mites, periannexal infil) AbsOP099 @RheumNow #EULAR2026 https://t.co/yQSc6u4oYV
Psoriatic arthritis #PsA sessions raised important topics on intercepting arthritis in psoriasis, treating obesity as a

Antoni Chan MD (Prof) synovialjoints

1 month 3 weeks ago
Psoriatic arthritis #PsA sessions raised important topics on intercepting arthritis in psoriasis, treating obesity as a disease target, synovial biopsy to guide treatment, molecular imaging to reveal subclinical disease. More tomorrow. #Rheumatology @RheumNow #EULAR2026
Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease outcomes. Two randomized controlled trials presented at EULAR 2026 add to this growing literature in PsA and RA. However, before we start prescribing Mediterranean diets, the data deserve a closer look.
Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care

Antoni Chan MD (Prof) synovialjoints

1 month 3 weeks ago
Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+
It's unclear whether GLP-1agonists inmpvove PsA from weight loss or other MoA

74 PsA patients on GLP-1RA vs 74 matched

Aurelie Najm AurelieRheumo

1 month 3 weeks ago
It's unclear whether GLP-1agonists inmpvove PsA from weight loss or other MoA 74 PsA patients on GLP-1RA vs 74 matched controls (BMI + disease activity matched) After adjusting for BMI change PROs still improve cDAPSA (-0.4/mo) DAPSA (-0.6/mo) and pain but not SJC, TJC or CRP https://t.co/dcaU2jwbKJ
Guselkumab gets FDA Nod for X-ray Protection

The U.S. Food and Drug Administration (FDA) has approved Johnson & Jo

Dr. John Cush RheumNow

1 month 3 weeks ago
Guselkumab gets FDA Nod for X-ray Protection The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in https://t.co/tlH7WM5gil
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.
#OP0114 at #EULAR2026: Spanish study finds marked regional disparities in premature mortality from systemic connective t

Mrinalini Dey DrMiniDey

1 month 3 weeks ago
#OP0114 at #EULAR2026: Spanish study finds marked regional disparities in premature mortality from systemic connective tissue diseases. Higher socioeconomic deprivation and longer waits for specialist care were both linked to worse outcomes. @RheumNow https://t.co/04we2H0wdb
×